Arrowhead Pharmaceuticals Investor Relations Material
Latest events
Q1 2024
Arrowhead Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Arrowhead Pharmaceuticals Inc
Access all reports
Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of intractable diseases in the United States. Its two platform technology includes a subcutaneous gene therapy program, which is focused on developing RNAi candidates targeting RNA sequences that are not amenable to conventional oral delivery through compacted, double-stranded RNA formulations for liver targeted delivery; and peptide platform technology that enables subcutaneous delivery of biologically active oligonucleotide payloads without the need for liposomal or polymeric encapsulation systems.
Key slides for Arrowhead Pharmaceuticals Inc
R&D Day 2023
Arrowhead Pharmaceuticals Inc
R&D Day 2023
Arrowhead Pharmaceuticals Inc
Latest articles
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Companies That Had Their IPO in 2022: War, Inflation and Interest Rates
The stock market and IPO landscape in 2022 was marked by inflationary pressures, rate hikes, and war that heavily impacted the market sentiment.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States